The DOI matches its Crossref record; 251 of the 257 references it cites were found in a registry or an index.
Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline
Open accessAbstract
OBJECTIVE: To update practice guidelines for the therapeutic use of androgens in women. PARTICIPANTS: A Task Force appointed by the Endocrine Society, American Congress of Obestricians and Gynecologists (ACOG), American Society for Reproductive Medicine (ASRM), European Society of Endocrinology (ESE), and International Menopause Society (IMS) consisting of six experts, a methodologist, and a medical writer. EVIDENCE: The Task Force commissioned two systematic reviews of published data and considered several other existing meta-analyses and trials. The GRADE methodology was used; the strength of a recommendation is indicated by a number "1" (strong recommendation, we recommend) or "2" (weak recommendation, we suggest). CONSENSUS PROCESS: Multiple e-mail communications and conference calls determined consensus. Committees of the Endocrine Society, ASRM, ACOG, ESE, and IMS reviewed and commented on the drafts of the guidelines. CONCLUSIONS: We continue to recommend against making a diagnosis of androgen deficiency syndrome in healthy women because there is a lack of a well-defined syndrome, and data correlating androgen levels with specific signs or symptoms are unavailable. We recommend against the general use of T for the following indications: infertility; sexual dysfunction other than hypoactive sexual desire disorder; cognitive, cardiovascular, metabolic, or bone health; or general well-being. We recommend against the routine use of dehydroepiandrosterone due to limited data concerning its effectiveness and safety in normal women or those with adrenal insufficiency. We recommend against the routine prescription of T or dehydroepiandrosterone for the treatment of women with low androgen levels due to hypopituitarism, adrenal insufficiency, surgical menopause, pharmacological glucocorticoid administration, or other conditions associated with low androgen levels because there are limited data supporting improvement in signs and symptoms with therapy and no long-term studies of risk. Evidence supports the short-term efficacy and safety of high physiological doses of T treatment of postmenopausal women with sexual dysfunction due to hypoactive sexual desire disorder. Importantly, endogenous T levels did not predict response to therapy. At present, physiological T preparations for use in women are not available in many countries including the United States, and long-term safety data are lacking. We recommend that any woman receiving T therapy be monitored for signs and symptoms of androgen excess. We outline areas for future research. Ongoing improvement in androgen assays will allow a redefinition of normal ranges across the lifespan; this may help to clarify the impact of varying concentrations of plasma androgens on the biology, physiology, and psychology in women and lead to indications for therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedDiagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,842
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.8.606 · Cited by 1,799
ORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349
Atkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., Liberati, A., O'Connell, D., Oxman, A. D., Phillips, B., et al. (2004) · BMC Health Services Research · doi:10.1186/1472-6963-4-38 · Cited by 1,235
ANDERSON, D. C. (1974) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1974.tb03298.x · Cited by 1,127
Södergard, R., Bäckström, T., Shanbhag, V., & Carstensen, H. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90038-3 · Cited by 1,080
Research works printed but not linked: 6
- [13]13. Braunstein GD, Reitz RE, Buch A, Schnell D, Caulfield MP. Tes- tosterone reference ranges in normally cycling healthy premeno- pausal women. J Sex Med. 2011;8:2924 -2934.
- [28]28. Ly LP, Sartorius G, Hull L, et al. Accuracy of calculated free tes- tosterone formulae in men. Clin Endocrinol (Oxf). 2010;73:382- 388.
- [31]31. Rosner W. An extraordinarily inaccurate assay for free testoster- one is still with us. J Clin Endocrinol Metab. 2001;86:2903.
- [179]179. Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hyster- ectomy and sexual functioning. JAMA. 1999;282:1934 -1941.
- [182]182. Snabes MC, Zborowski J, Simes S. Libigel (testosterone gel) does not differentiate from placebo therapy in the treatment of hypo- active sexual desire in postmenopausal women. J Sex Med. 2012; 3:171.
- [195]195. Anderson KE, Sellers TA, Chen PL, Rich SS, Hong CP, Folsom AR. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa. Cancer. 1997;79:494 -499.
Cited by
Sorted by citations
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R., Panay, N., & Fenton, A. J. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 968
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationThe Menopause Transition: Signs, Symptoms, and Management Options
Santoro, N. F., Roeca, C. M., Peters, B. A., & Neal-Perry, G. S. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa764 · Cited by 774
Self-citationLong-term health consequences of premature or early menopause and considerations for management
Faubion, S. S., Kuhle, C. L., Shuster, L. T., & Rocca, W. A. (2015) · Climacteric · doi:10.3109/13697137.2015.1020484 · Cited by 566
Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause
Sullivan, S. D., Sarrel, P. M., & Nelson, L. M. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.09.046 · Cited by 519
Metadata
- Authors
- Wierman, M. E., Arlt, W., Basson, R., Davis, S. R., Miller, K. K., Murad, M. H., Rosner, W., & Santoro, N.
- Affiliations
- University of British Columbia (CA)
- University of Birmingham (GB)
- Veterans Health Administration (US)
- Massachusetts General Hospital (US)
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-10
- Volume
- 99
- Issue
- 10
- Pages
- 3489-3510
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2169638329
- Semantic Scholar
- 0ab9fec7488d4092d18727dbe6ea5d548da84c6e
- Cited by
- 363
- References
- 257
- Citations by year
- 2026: 18 · 2025: 24 · 2024: 27 · 2023: 22 · 2022: 52 · 2021: 46 · 2020: 28 · 2019: 25 · 2018: 31 · 2017: 27 · 2016: 34 · 2015: 25 · 2014: 3
- FWCI
- 23.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- androgen therapy, women, testosterone, dehydroepiandrosterone, hypoactive sexual desire disorder, postmenopausal women, adrenal insufficiency, hypopituitarism, surgical menopause, hyperandrogenism, infertility, sexual dysfunction, bone health, cardiovascular risk, treatment safety
- MeSH terms
- Contraindications, Androgens, Endocrinology, Female, Humans, Hypopituitarism, Societies, Medical, Practice Guidelines as Topic, Evidence-Based Medicine, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
